ORAL LAQUINIMOD FOR MULTIPLE SCLEROSIS GRANTED FAST TRACK STATUS BY FDA

 | Quelle: Active Biotech AB Active Biotech AB 

Jerusalem, Israel and Lund, Sweden, February 12, 2009 - Teva
Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech
(NASDAQ OMX NORDIC: ACTI) today announced that oral laquinimod, an
investigational treatment for relapsing-remitting multiple sclerosis
(RRMS), has received a Fast Track designation from the U.S. Food and
Drug Administration (FDA). Teva completed enrollment for the first of
its two Phase III clinical trials for laquinimod (ALLEGRO) in
November 2008 and is currently enrolling RRMS patients globally for
the second Phase III study (BRAVO).

Contact: Elana Holzman    Teva Pharmaceutical       +972-(3)-926-7554
         Kevin Mannix     Industries Ltd.           +1-(215)-591-8912
                          Teva North America
Contact: Tomas Leanderson Active Biotech AB         +46-46-19-20-95
         Göran Forsberg   Active Biotech AB         +46-46-19-11-54

Anhänge

ORAL LAQUINIMOD FOR MULTIPLE SCLEROSIS GRANTED FAST TRACK STATUS BY FDA.pdf